Patients with connective tissue disorders and increased thrombotic risk need personalized anticoagulant therapy. Key considerations include the specific disorder type, the presence of antiphospholipid antibodies, potential drug interactions, and patient’s bleeding risk. Regular monitoring and adjustment of dosages are critical.